The Cooper Companies, Inc. (COO) Q4 2025 Earnings Call Transcript

Cooper Companies hosted its Q4 and full-year 2025 earnings conference call on December 4, 2025, led by CEO Al White and CFO Brian Andrews with Kim Duncan moderating. The prepared remarks state the call will review reported results and guidance and include forward-looking comments on revenue, EPS, cash flows, interest, FX and tax rates and tariffs; a broad group of sell-side analysts participated. The excerpt contains no raw financial figures or updated quantitative guidance.

Analysis

Market structure: Cooper (COO) sits on the premium contact‑lens and women's health stacks where scale and distribution matter; an earnings call emphasizing FX/tariff sensitivity implies near‑term margin volatility but sustained revenue durability from recurring contact‑lens demand and fertility services. Direct winners: vertically integrated suppliers and global distributors (benefit from volume recovery); losers: small private competitors with less pricing power and FX hedging. Cross‑asset: a meaningful beat/raise would tighten COO credit spreads (benefit bond holders) and compress implied equity volatility; a miss would widen IG spreads and lift USD demand if management flags unhedged FX losses.

Risk assessment: Tail risks include an adverse FDA action or material litigation in fertility products, a China/Taiwan supply shock, or punitive tariffs that could knock 200–400bp off adjusted operating margin (low probability, high impact). Immediate risk (days): post‑call sentiment and options gamma; short term (weeks–months): FX moves and price promotions; long term (quarters–years): demographic trends (myopia, fertility) and successful integration of acquisitions. Hidden dependencies: supplier single‑sourcing for silicone hydrogel materials and mileage on acquired CooperSurgical synergies; catalysts include quarterly guidance, FDA approvals, and tariff rulings within 30–90 days.

Trade implications: If COO sells off >5% intraday, consider establishing a 2–3% long equity position targeting +15–25% in 6–12 months, with stop at −10% and scale in on further weakness; alternatively, buy a 6–9 month call spread (e.g., 1x long 12% OTM / short 25% OTM) to cap cost if implied vol >30%. For downside-insurance, buy 3‑month puts if guidance implies >100bp margin downside, or sell weekly OTM puts to collect premium if you accept assignment. Sector tilt: overweight medical devices/eye care, underweight consumer durables; rotate 1–3% from cyclical retail into COO/ALC‑like names over next 30–90 days.

Contrarian angles: The market may be overstating FX/tariff transience and understating recurring revenue resilience — if management highlights hedges, a 5–10% pullback would be a buying window. Historical parallels: post‑M&A margin compression in medtech typically reverts in 12–18 months as SG&A synergies materialize; missing that reversion is a common mispricing. Unintended consequence: aggressive cost cuts to mollify margins could underinvest R&D, ceding share to specialty challengers — watch R&D and CapEx guidance for signs of myopic cuts.

Key Decisions for Investors

• Establish a 2–3% long position in COO if the stock drops >5% on earnings; target +15–25% upside over 6–12 months, set a hard stop at −10%, and scale in further on any additional 5% declines.
• Buy a 6–9 month call spread on COO (long ~12% OTM / short ~25% OTM) sized to 1–2% portfolio risk if implied vol >30%, to play asymmetric upside while capping premium outlay.
• If guidance flags >100bp margin risk or material FX exposure, purchase 3‑month protective puts (5–7% OTM) sized to 1% portfolio to hedge downside risk during the next two guidance updates.
• Rotate 1–3% portfolio weight from cyclical consumer names into medical devices/eye care (COO and Alcon‑style exposure) over the next 30–90 days, prioritizing names with >50% recurring revenue and >15% gross margin.
• Monitor three specific catalysts over the next 30–90 days before adding size: (1) next-quarter revenue/gross‑margin guidance, (2) any tariff rulings or announced FX hedge coverage, and (3) FDA or regulatory notices on CooperSurgical products; increase position if two of three are positive.